Avecho Biotechnology's total inventories for the quarter that ended in Dec. 2025 was $0.01 Mil. Avecho Biotechnology's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was $0.05 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Avecho Biotechnology's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $-0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Avecho Biotechnology's Days Inventory for the
six
months ended in Dec. 2025 was 70.48.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Avecho Biotechnology's Inventory Turnover for the quarter that ended in Dec. 2025 was 2.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Avecho Biotechnology's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.10.
Avecho Biotechnology (OTCPK:AVEFF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Avecho Biotechnology's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Avecho Biotechnology's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Avecho Biotechnology Total Inventories Related Terms
Avecho Biotechnology Total Inventories Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Avecho Biotechnology (AVEFF) has a Total Inventories of $0.01 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Avecho Biotechnology and its competitors.
Is Avecho Biotechnology's Total Inventories too high?
Avecho Biotechnology's current Total Inventories is $0.01 Mil.
How does Avecho Biotechnology's Total Inventories compare to VRTX and REGN?
Avecho Biotechnology's Total Inventories of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Avecho Biotechnology and its competitors. Avecho Biotechnology's current Total Inventories is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (AVEFF) has a current Total Inventories of $0.01 Mil. The current Total Inventories is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Avecho Biotechnology (AVEFF), the current Total Inventories is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVEFF has been successfully added to your 